company background image
RPRX

Royalty Pharma NasdaqGS:RPRX Stock Report

Last Price

US$42.98

Market Cap

US$26.1b

7D

0.3%

1Y

2.6%

Updated

27 Nov, 2022

Data

Company Financials +
RPRX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance1/6
Financial Health3/6
Dividends2/6

RPRX Stock Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.

Royalty Pharma plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Royalty Pharma
Historical stock prices
Current Share PriceUS$42.98
52 Week HighUS$44.75
52 Week LowUS$36.15
Beta0.34
1 Month Change0.51%
3 Month Change1.56%
1 Year Change2.60%
3 Year Changen/a
5 Year Changen/a
Change since IPO-3.42%

Recent News & Updates

Recent updates

The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Apr 25
The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Jan 25
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Jan 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Key Things To Watch Out For If You Are After Royalty Pharma plc's (NASDAQ:RPRX) 1.6% Dividend

Mar 08
Key Things To Watch Out For If You Are After Royalty Pharma plc's (NASDAQ:RPRX) 1.6% Dividend

Do Insiders Own Lots Of Shares In Royalty Pharma plc (NASDAQ:RPRX)?

Feb 01
Do Insiders Own Lots Of Shares In Royalty Pharma plc (NASDAQ:RPRX)?

Are Royalty Pharma's (NASDAQ:RPRX) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Dec 28
Are Royalty Pharma's (NASDAQ:RPRX) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Are Investors Undervaluing Royalty Pharma plc (NASDAQ:RPRX) By 40%?

Nov 30
Are Investors Undervaluing Royalty Pharma plc (NASDAQ:RPRX) By 40%?

Shareholder Returns

RPRXUS PharmaceuticalsUS Market
7D0.3%1.6%1.3%
1Y2.6%9.9%-18.5%

Return vs Industry: RPRX underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: RPRX exceeded the US Market which returned -18.5% over the past year.

Price Volatility

Is RPRX's price volatile compared to industry and market?
RPRX volatility
RPRX Average Weekly Movement2.8%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: RPRX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: RPRX's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996n/aPablo Legorretahttps://www.royaltypharma.com

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Royalty Pharma plc Fundamentals Summary

How do Royalty Pharma's earnings and revenue compare to its market cap?
RPRX fundamental statistics
Market CapUS$26.10b
Earnings (TTM)US$506.82m
Revenue (TTM)US$2.25b

37.4x

P/E Ratio

8.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RPRX income statement (TTM)
RevenueUS$2.25b
Cost of RevenueUS$861.90m
Gross ProfitUS$1.39b
Other ExpensesUS$878.45m
EarningsUS$506.82m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.15
Gross Margin61.64%
Net Profit Margin22.55%
Debt/Equity Ratio68.3%

How did RPRX perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

64%

Payout Ratio